LENSAR Inc
NASDAQ:LNSR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
LENSAR Inc
Non-Reccuring Items
LENSAR Inc
Non-Reccuring Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Non-Reccuring Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
LENSAR Inc
NASDAQ:LNSR
|
Non-Reccuring Items
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Non-Reccuring Items
-$413m
|
CAGR 3-Years
12%
|
CAGR 5-Years
16%
|
CAGR 10-Years
10%
|
|
|
Edwards Lifesciences Corp
NYSE:EW
|
Non-Reccuring Items
-$531.4m
|
CAGR 3-Years
-94%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-54%
|
|
|
Stryker Corp
NYSE:SYK
|
Non-Reccuring Items
-$836m
|
CAGR 3-Years
3%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-8%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Non-Reccuring Items
-$740m
|
CAGR 3-Years
-79%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-23%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Non-Reccuring Items
-$9.8m
|
CAGR 3-Years
22%
|
CAGR 5-Years
9%
|
CAGR 10-Years
3%
|
|
LENSAR Inc
Glance View
LENSAR, Inc. engages in the development of femtosecond laser technology for refractive cataract surgery. The company is headquartered in Orlando, Florida and currently employs 110 full-time employees. The company went IPO on 2020-09-21. The firm is focused on designing, developing, and marketing femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. The company has developed the LENSAR Laser System to provide an alternative laser cataract treatment tool that allows the surgeon to better address astigmatism and improve visual outcomes. Its product portfolio consists of the LENSAR Laser System with Streamline IV and IntelliAxis and its associated consumable components. The company is also developing an integrated cataract treatment system, ALLY, which is designed to combine its existing femtosecond laser technology with phacoemulsification system into a single unit and allow surgeons to perform each of the critical steps in a cataract procedure in a single operating room using this device.
See Also
What is LENSAR Inc's Non-Reccuring Items?
Non-Reccuring Items
0
USD
Based on the financial report for Dec 31, 2025, LENSAR Inc's Non-Reccuring Items amounts to 0 USD.
